HOUSTON, TX Dec. 11 , 2008. Pharm-Olam International (POI) a multi-national, full service CRO to the pharmaceutical and biotech industries announced the expansion of its rescue study services to assist sponsors with challenging ongoing studies.
In making the announcement, Dr. Zev Munk, POI's Chief Executive Officer cited the company's growth to 600 employees in 2008, including several local regulatory experts and logistics managers to POI's Rescue Start-Up Team.
“Our Rescue Start-Up Team understands every aspect of turning a study around quickly and work in parallel to achieve regulatory approval, site agreements and logistical requirements,” said Dr. Munk. “Their success in reducing timelines underscores our commitment to our customer's enrollment goals and exceeding standards.”
POI's Rescue Start-Up Team quickly analyzes options for enrollment including: additional countries, new sites within existing countries, and assessing active sites with potential for improvement.
“Pharm-Olam continues to deliver comprehensive clinical development services to the life science industries ,” said Dr. Munk. “ Our staff growth allows us to broaden the geographic breadth and depth of those services to our customers in targeted regions worldwide.”
For more information about Pharm-Olam please contact Iain Gordon, VP of Commercial and Corporate Affairs at email@example.com or John Hovre, Chief Operating Officer at firstname.lastname@example.org.
About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.